Details of the Drug

General Information of Drug (ID: DMNI3U2)

• Drug Name: ZIMELIDINE
• Synonyms: Prestwick0_000092; Prestwick1_000092; 56775-88-3; AC1L26VA; NCIStruc1_001846; NCIStruc2_001359; SPBio_001983; 2-Propen-1-amine, 3-(4-bromophenyl)-N,N-dimethyl-3-(3-pyridinyl)-; CTK1F3832; OYPPVKRFBIWMSX-UHFFFAOYSA-N; DB04832; NCI60_002580; FT-0675907; N,N-dimethyl-3-(4-bromophenyl)-3-(pyrid-3-yl)allylamine; N,N-dimethyl-3-(4-bromophenyl)-3-(3-pyridyl)-allylamine; (Z)-3-[1-(p-Bromophenyl)-3-(dimethylamino)propenyl]pyridine; 3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-3-ylprop-2-en-1-amine

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Withdrawn from market	[1], [2]
Major depressive disorder	6A70.3	Withdrawn from market	[3]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 317.22
  Topological Polar Surface Area (xlogp); 3.9
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 2
• ADMET Property:
  Clearance: The drug present in the plasma can be removed from the body at the rate of 13.8 mL/min/kg [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 8.4 +/- 2.0 hours [4]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.086% [4]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 6.8 L/kg [4]
• Chemical Identifiers:
  Formula: C16H17BrN2
  IUPAC Name: (Z)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-3-ylprop-2-en-1-amine
  Canonical SMILES: CN(C)C/C=C(/C1=CC=C(C=C1)Br)\\C2=CN=CC=C2
  InChI: InChI=1S/C16H17BrN2/c1-19(2)11-9-16(14-4-3-10-18-12-14)13-5-7-15(17)8-6-13/h3-10,12H,11H2,1-2H3/b16-9-
  InChIKey: OYPPVKRFBIWMSX-SXGWCWSVSA-N
• Cross-matching ID:
  PubChem CID: 5365247
  ChEBI ID: CHEBI:92824
  CAS Number: 56775-88-3
  DrugBank ID: DB04832
  TTD ID: D0C1XS

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Inhibitor	[5]

Molecular Expression Atlas of This Drug

• ICD Disease Classification: 06 Mental, behavioural or neurodevelopmental disorder
• Disease Class: ICD-11: 6A20 Schizophrenia
• The Studied Tissue: Pre-frontal cortex
• The Studied Disease: Major depressive disorder [ICD-11:6A20]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Serotonin transporter (SERT)	DTT	SLC6A4	1.17E-01	0.07	0.59

References

• [1] Pharmacokinetic study of zimelidine using a new GLC method. Clin Pharmacokinet. 1983 Nov-Dec;8(6):530-40.
• [2] The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness of narcoleptic patients. Clin Neuropharmacol. 1986;9(1):46-51.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins. J Med Chem. 1984 Nov;27(11):1508-15.
• [6] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
• [7] Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [9] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [10] Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
• [11] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [12] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.